GlobalData on MSN3d
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III
UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
Daily Express12d
Landmark UK drug trial called LION aims to maul the world's toughest cancers
A revolutionary new drug trial called LION aims to ravage the ... a cancer immunologist from the Cancer Research UK Manchester Institute, University of Manchester. With plans to recruit 89 ...
Fierce Pharma2d
AstraZeneca offers early look at Datroway-Tagrisso combo in EGFR lung cancer as phase 3 trial rolls on
As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...
PharmaTimes11d
Dementia drug neflamapimod shows positive phase 2b trial results
our working hypothesis for the failure of neflamapimod during the initial 16 weeks of the study is that the investigational drug capsules utilised in that phase of the trial delivered lower than ...
The Pharma Letter4d
Eneboparatide met primary Phase III endpoint, says AstraZeneca
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...